Medpace is on pace to bring new drugs to market. The contract research organization (CRO) offers clinical trial management and regulatory consulting to pharmaceutical and biotech companies that are developing new drug candidates in the areas of cardiology, metabolism, and oncology. Its services include clinical development planning, data management, laboratory services, quality assurance auditing, regulatory document preparation, safety surveillance, and statistical analysis. Its Web-based ClinTrak tool allows users to access and track real-time clinical study data and metrics. Medpace serves customers worldwide through offices in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

AAIPharma provides contract research services to the pharmaceutical, biotech, and medical device industries. Its outsourcing services run the gamut from drug candidate selection and feasibility studies, to bioanalytical testing and clinical trials management. Its early clinical development division helps evaluate potential compounds and design patient studies. The company's clinical development businesses run large clinical trials for customers around the world. Other services include regulatory support and data management. AAIPharma has divested its pharmaceutical development division, which cranked out small batches of drugs to supply clinical trials and develops oral drug delivery technology.

Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company’s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.

Isotechnika Pharma may have isolated a new drug to combat organ rejection. Lead drug candidate voclosporin could replace cyclosporine as the immunosuppressant of choice for organ transplant recipients and patients with autoimmune conditions. Studies indicate it is more effective and has fewer side effects than cyclosporine. Isotechnika is testing the drug for kidney transplant recipients and psoriasis. Minority shareholder Paladin Labs has signed on to develop and market the drug in certain markets. Its Isotechnika Diagnostics division sells "breathalyzer" tests to diagnose H. pylori infections, which cause chronic gastritis and ulcers.

Viventia Biotechnologies Inc., a biopharmaceutical company, offers a portfolio of novel antibody-based drugs for the treatment of cancer. Its lead product, Proxinium is used for the treatment of head and neck cancer. The company also offers Vicinium, a product for the treatment of bladder cancer; and VB6-845, a product for the treatment of solid tumors. Viventia specializes in the discovery and development of a portfolio of monoclonal antibodies for the treatment of common cancers. It also has a location in Winnipeg, Canada. The company was formerly known as Novopharm Biotech, Inc. and changed its name to Viventia Biotech, Inc. in 2000. The company was is headquartered in Mississauga, Canada. As of December 28, 2005, Viventia Biotechnologies Inc. operates as a subsidiary of Dan Family Holdings, Ltd.

Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California. Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen Therapeutics's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity.

Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Kailua-Kona, Hawaii. Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Mera Pharmaceuticals company's product line consists of ASTAFACTOR, a nutraceutical and source of natural astaxanthin; and SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids. It markets its products to retail outlets in Hawaii through distribution arrangements with established companies.

Teva Pharmaceuticals USA is the leading generic pharmaceutical company, marketing products from a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, oncolytic, antidiabetic, analgesic, dermatology, respiratory, and women's healthcare. Dosage forms include tablets and capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. Teva USA products are marketed to chains, wholesalers, distributors and government agencies, as well as in health systems and oncology settings. Teva USA has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry. The company's mission is to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Aspreva Pharmaceuticals believes that bad aim can be a good thing when treating diseases. This company conducts clinical trials to find new uses for approved drugs. As a result, partners team up with Aspreva to gain incremental revenue from the commercialization of the new version of the drug. Working in collaboration with Roche, Aspreva conducts clinical trials to investigate the use of Roche's CellCept (indicated for prevention of rejection in organ transplant patients) to treat autoimmune diseases including lupus nephritis and pemphigus vulgaris. Aspreva is a subsidiary of Swiss pharmaceutical firm Galenica Group.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.